SCHEMBL2290886

SCHEMBL2290886

CCCNC(=O)NS(=O)(=O)c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.72
LMNA P02545 2/20 0.72
TSHR P16473 2/20 0.72
CYP3A4 P08684 1/20 0.72
THRB P10828 1/20 0.72
NFKB1 P19838 1/20 0.72
HTR2A P28223 1/20 0.72
CYP2C19 P33261 1/20 0.72
ADRA1A P35348 1/20 0.72
SMN1; SMN2 Q16637 1/20 0.72
NPSR1 Q6W5P4 1/20 0.72
CYP2C9 P11712 2/20 0.61
ALB P02768 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
FBP1 P09467 10/20 0.59
CA12 O43570 1/20 0.59
CA1 P00915 1/20 0.59
CA2 P00918 1/20 0.59
CA9 Q16790 1/20 0.59
KDM4E B2RXH2 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL184964 0.90 CYP2C9 (0.76) ALDH1A1LMNATSHRCYP3A4THRB
SCHEMBL11049679 0.89 CYP2C9 (0.69) ALDH1A1LMNATSHRCYP3A4THRB
Methyl Alcohol SCHEMBL28260710 0.89 CYP2C9 (0.74) ALDH1A1LMNATSHRCYP3A4THRB
SCHEMBL28534045 0.88 EPHX2 (0.68) ALDH1A1LMNATSHRCYP2C9ALB
SCHEMBL19271872 0.88 EPHX2 (0.68) ALDH1A1LMNATSHRCYP2C9ALB
SCHEMBL10607611 0.86 KDM4E (0.68) ALDH1A1LMNATSHRCYP3A4THRB
SCHEMBL24075260 0.85 ALDH1A1 (0.75) ALDH1A1LMNATSHRCYP3A4THRB
SCHEMBL14273616 0.85 ALDH1A1 (0.83) ALDH1A1LMNATSHRCYP3A4THRB
Chlorpropamide SCHEMBL20770748 0.85 ALDH1A1 (0.82) ALDH1A1LMNATSHRCYP3A4THRB
SCHEMBL5931108 0.85 FBP1 (0.70) ALDH1A1LMNATSHRSMN1; SMN2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0644188-A1 Process for the preparation of sulfur derivatives of imidazole and intermediates obtained ROUSSEL UCLAF (FR) 1995-03-22 EP claimed
EP-2892919-A1 FUSION PROTEINS FOR TREATING A METABOLIC SYNDROME SANOFI (FR) 2015-07-15 EP disclosed
WO-2014074668-A1 MODULATORS OF GPR119 AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2014-05-15 WO disclosed
WO-2014037373-A1 FUSION PROTEINS FOR TREATING A METABOLIC SYNDROME SANOFI (FR) 2014-03-13 WO disclosed
WO-2012145604-A1 MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2012-10-26 WO disclosed
WO-2011089203-A1 PHARMACEUTICAL COMPOSITION FOR TREATING A METABOLIC SYNDROME SANOFI-AVENTIS (FR) 2011-07-28 WO disclosed
US-20060100324-A1 Polyolefin resin composition containing diacetal API CORPORATION (JP) 2006-05-11 US disclosed
EP-0644188-B1 Process for the preparation of sulfur derivatives of imidazole and intermediates obtained AVENTIS PHARMA SA (FR) 2002-12-04 EP disclosed
EP-0644188-A1 Process for the preparation of sulfur derivatives of imidazole and intermediates obtained ROUSSEL UCLAF (FR) 1995-03-22 EP disclosed